International CSRC Investment Holdings Co. Ltd. engages in the production of carbon black, a material mostly used in the manufacture of rubber. It operates through the following segments: Carbon Black, Biotechnology, Battery Product, and Others. The Carbon Black segment produces and sells soot, synthetic rubber, and steam. The Biotechnology segment develops new drugs. The Battery Product segment manufactures, assembles, and sells battery core and battery pack products. The company was founded by Chen Fu Ku and Po Shou Lin on June 15, 1973 and is headquartered in Taipei, Taiwan.

Merck Sharp & Dohme Corp. engages in the research, development, and distribution of vaccines, prescription drugs, and animal health products. The company is headquartered in Whitehouse Station, NJ.

The Dutch Cancer Society (DCS; in Dutch: 'KWF Kankerbestrijding' ) is a Dutch Society committed to fight cancer by scientific research, education, patient support and fundraising in cooperation with volunteers, donors, patients, doctors and researchers. By this commitment, DCS targets less cancer, more cures and a higher quality of life for cancer patients. Its motto is, 'Everyone Deserves a Tomorrow' .

Genomic Health, Inc. (NASDAQ: GHDX) is a provider of genomic-based diagnostic tests that address both the overtreatment and optimal treatment of early-stage cancer, one of the greatest issues in healthcare today. The company is applying its world-class scientific and commercial expertise and infrastructure to lead the translation of massive amounts of genomic data into clinically-actionable results for treatment planning throughout the cancer patient's journey, from diagnosis to treatment selection and monitoring. The company is based in Redwood City, California, with European headquarters in Geneva, Switzerland.

Veridex, LLC, a Johnson & Johnson company, is an organization dedicated to providing physicians and patients with high-value in vitro diagnostic oncology products.Veridex’s products will significantly benefit patients through earlier disease detection, and will enable personalized strategies to improve patient management and outcomes.

Ganymed Pharmaceuticals AG is a biopharmaceutical company with the mission of revolutionizing cancer treatment by developing a new class of therapeutic drugs called Ideal Monoclonal Antibodies (IMABs). IMABs are unique in that they are highly selective for proteins which are present on tumor cells, but do not bind to healthy cells. This unmatched tumor cell specificity makes IMABs cancer cell selective allowing them to efficiently kill tumor cells without harming normal healthy tissues. They can thus be administered at optimal dose and have a broad therapeutic window with reduced risks of side effects.

Shanghai Shanzhun Biotechnology Co., Ltd., established on 2015-07-16, Business scope includes licensed projects:Import and export;Technology Import and Export.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments) General project:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Chemical product production(No licensed chemical products);Sales of Class I Medical Devices;Instrument sales;electronics sales.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

NETRIS Pharma SAS is a French company located in Lyon that develops targeted therapies for the treatment of cancer. The firm was founded in 2008 by Agnès Bernet and Patrick Mehlen. Patrick Mehlen has been the CEO since the company founding.\nThe company says this about itself: NETRIS Pharma, a clinical-stage company designs and develops anti-cancer therapeutic molecules, particularly monoclonal antibodies, to block the interaction between dependence receptors and their ligands. NETRIS Pharma, based in Lyon, is the world most advanced biopharmaceutical company targeting netrin-1.

Applera Corp. manufactures medical instruments

Celera Corp. provides medical diagnostics services. It offers disease management solutions through a combination of tests and services based on genetics discovery platforms. Celera was founded in 1998 and is headquartered in Alameda, CA.

Zhejiang Cancer Hospital is a Chinese private company located in Hangzhou. The firm operates as an cancer hospital.

Rosetta Inpharmatics LLC designed and implemented DNA microarray gene expression systems. The company provided software for use in informational genomics. The company was founded in may 29, 2009 and was headquartered in Seattle, WA.

Castle Biosciences is a biotech company that develops and validates diagnostic tests and technologies for the treatment of cancer. The company also focused on providing physicians and patients with personalized, clinically actionable genomic information to make more accurate treatment plan decisions. The DecisionDx family of molecular diagnostic tests have the ability to meaningfully impact how cancers are diagnosed and managed and the DecisionDx-Melanoma predicts risk of recurrence or metastasis for patients with invasive cutaneous melanoma, a deadly skin cancer, including the risk of sentinel lymph node positivity. Castle Biosciences was founded in 2008 and is headquartered in Friendswood, Texas, United States.

sigma-tau is one of the most important Italian pharmaceutical groups, with a major presence also on the international stage. For more than half a century the company has been active in promoting the quality of life of man and his health. sigma-tau is present today in the most advanced research sectors, maintaining constant relations with scientific institutions with a world-wide reputation in the development of joint projects and in the implementation of original and innovative research programs. These results are the fruit of substantial, ongoing investment in research in the field of pharmaceutical innovation and stem not only from the efforts made to produce new products but also from the success of the company’s consolidated products. Bearing witness to sigma-tau’s achievements are not only the principles and values that inspire our efforts - innovation, dialogue and transparency, ethics, sustainability - but also the facts that have made sigma-tau a leading company in the research, manufacture and marketing of drugs.

Hangzhou Yitu Medical Technology Co., Ltd., established on 2017-03-08, Business scope includes technology development in the medical field,Technical Services,technical consulting,Achievement transfer;Computer software and hardware and image transmission processing software and hardware system design,Development and after-sales service;Network engineering design and construction;Sales:medical instrumentsIkind,medical instrumentsIIkind,Class III medical device,Computer hardware and software;Production:Class II Medical Devices,Class III medical device.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)(Subject to the scope of business approved by the company registration authority)